{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-115767","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2024-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.515732+00:00","generated_at":"2026-05-30T12:32:41.754050+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"enGene announces executive changes: new CTO, CSO, and President; Sullivan separation","bullets":["Joan Connolly appointed CTO effective Oct 21; brings 30+ yrs experience from Albireo, Stemline, Bristol-Myers.","Anthony Cheung transitions from CTO to CSO; James Sullivan departs Oct 31, 2024.","Sullivan separation agreement includes $485k salary continuation, prorated bonus, equity acceleration, option extension.","Alexander Nichols becomes Chief Strategy & Operations Officer; CEO Ron Cooper adds President title.","Detalimogene pivotal study ongoing; enGene expects BLA submission mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-115767","json":"https://secwatch.observer/filing/0000950170-24-115767.json","markdown":"https://secwatch.observer/filing/0000950170-24-115767.md","text":"https://secwatch.observer/filing/0000950170-24-115767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/engn-20241016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:32:41.754050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01f44d14b6","claim":"Anthony Cheung was appointed as Chief Scientific Officer at enGene Therapeutics Inc..","evidence_excerpt":"Dr. Anthony Cheung’s title and role changed from Chief Technology Officer to Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"4fcd308eb9","claim":"Ronald H.W. Cooper changed role as President at enGene Therapeutics Inc..","evidence_excerpt":"Mr. Ronald H.W. Cooper, assumed the additional title of President","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed additional title of President"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"87d40fe2c4","claim":"James Sullivan departed as Chief Scientific Officer at enGene Therapeutics Inc..","evidence_excerpt":"Dr. Sullivan shall depart the Company effective October 31, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"depart"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"bb89cb199d","claim":"Alexander Nichols was appointed as Chief Strategy and Operations Officer at enGene Therapeutics Inc..","evidence_excerpt":"Dr. Alexander Nichols’ title and role changed from President and Chief Operating Officer to Chief Strategy and Operations Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Strategy and Operations Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}